Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2024-08-13 Regulatory Filings
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2024-08-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification from Windlas Biotech Limited about the scheduling of a conference call to discuss the financial performance for the quarter ended June 30, 2024. It includes details such as date, time, and dial-in numbers for the call, and mentions key participants. There are no actual financial statements or detailed financial analysis included in the text. The document serves as an announcement of an upcoming conference call rather than the transcript or report of the call itself. Therefore, it fits the category of a Call Transcript (CT) announcement rather than the transcript itself. However, since the document is specifically about scheduling and inviting to a conference call, it aligns best with the Call Transcript (CT) category as it relates directly to the earnings call event. Confidence is high due to clear references to the conference call and financial quarter.
2024-08-06 English
Shareholders meeting
Regulatory Filings
2024-08-03 English
Board Meeting — WINDLAS BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 13-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for t…
Regulatory Filings
2024-08-02 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for August 13, 2024, to consider and approve the un-audited financial results for the quarter ended June 30, 2024. It is addressed to stock exchanges and mentions compliance with SEBI regulations. The document does not contain the financial results themselves but announces the upcoming meeting where these results will be approved. The document length is short (1878 characters) and serves as an announcement rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain substantive financial data or the actual report.
2024-08-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Windlas Biotech Limited addressed to stock exchanges (BSE and NSE) informing them about the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which mandates disclosure of such events. The document does not contain any financial data, results, or detailed reports but is an announcement of a scheduled event for investor interaction. The document length is short (2008 characters), and it serves as an informational notice rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.